Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eluminate-4: Elecoglipron in Type 2 Diabetes Mellitus with Impaired Renal Function
jRCT2031260268Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Randomised trial of elecoglipron in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in Hemoglobin A1c (HbA1c). Started Jul 2026; status: recruiting.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031260268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260268.